Title variants
Languages of publication
Abstracts
Propentofylline (PPT) is a drug used in the treatment of both vascular dementia and Alzheimer type dementia. Hydroxy-metabolites of propentofylline (OHPPT) also demonstrate the same biological activity as the parent compound. As steroisomers of HOPPT are not commercially available, we had to produce them for pharmacological and pharmacokinetic studies. The aim of this study was to find the strains of Saccharomyces cerevisiae yielding enantiomerically pure (R)- or (S)-1-(5-hydroxyhexyl)-3,5-dimethyl-7-propylxanthin (OHPPT) from PPT. In this paper, we present the results of stereoselective reduction of PPT into OHPPT when catalysed by whole cells of baker's and a few strains of wine yeast in water and organic solvents.
Discipline
Journal
Year
Issue
Pages
174-180
Physical description
References
Document Type
ARTICLE
Publication order reference
Elzbieta Pekala, Department of Technology and Biotechnology of Drugs,Medical College of Jagiellonian University, ul. Medyczna 9,30-688 Krakow, Poland
Identifiers
YADDA identifier
bwmeta1.element.element-from-psjc-4bb40bf5-4861-3e51-9ad4-d13361f47c41